Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | HRH1 | P35367 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.35 |
| ▸ | FOLH1 | Q04609 | 6/20 | 0.35 |
| ▸ | NAALAD2 | Q9Y3Q0 | 3/20 | 0.34 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8767807 | 1.00 | NOD1 (0.37) | NOD1CHRM1AKR1A1CHRM3HTR2A | |
| SCHEMBL20905719 | 0.93 | FOLH1 (0.37) | NOD1CHRM1AKR1A1CHRM3HTR2A | |
| SCHEMBL5220096 | 0.93 | FOLH1 (0.37) | NOD1CHRM1AKR1A1CHRM3HTR2A | |
| SCHEMBL4745785 | 0.86 | — | — | |
| SCHEMBL21621515 | 0.86 | — | — | |
| SCHEMBL1082586 | 0.86 | NOD1 (0.43) | NOD1FOLH1NAALAD2RIMKLAKDM4E | |
| SCHEMBL4745784 | 0.86 | — | — | |
| SCHEMBL201058 | 0.82 | CA2 (0.50) | NOD1CHRM1AKR1A1CHRM3HTR2A | |
| SCHEMBL429475 | 0.82 | CA2 (0.50) | NOD1CHRM1AKR1A1CHRM3HTR2A | |
| SCHEMBL288045 | 0.82 | CA2 (0.50) | NOD1CHRM1AKR1A1CHRM3HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230158179-A1 | RADIOPHARMACEUTICAL CONJUGATE COMPOSITIONS AND USES THEREOF | RAYZEBIO, INC. | 2023-05-25 | — | — | US | disclosed |
| EP-0581429-B1 | Process for synthesizing cyclic depsipeptides | TAKARA SHUZO CO (JP) | 1997-09-03 | — | — | EP | disclosed |
| EP-0581429-A2 | Process for synthesizing cyclic depsipeptides | TAKARA SHUZO CO. LTD. (JP) | 1994-02-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230158179-A1 | RADIOPHARMACEUTICAL CONJUGATE COMPOSITIONS AND USES THEREOF | PAICS, LNPEP, DNPEP | NOD1 4309/4885CHRM1 3894/4885AKR1A1 3328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.